Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype
- 1 July 2019
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 25 (13) , 3962-3973
Abstract
Purpose: Although ovarian clear cell carcinomas (OCCC) are commonly resistant to platinum-based chemotherapy, good clinical outcomes are observed in a subset of patients. The explanation for this is unknown but may be due to misclassification of high-grade serous ovarian cancer (HGSOC) as OCCC or mixed histology. Experimental Design: To discover potential biomarkers of survival benefit following platinum-based chemotherapy, we ascertained a cohort of 68 Japanese and Australian patients in whom progression-free survival (PFS) and overall survival (OS) could be assessed. We performed IHC reclassification of tumors, and targeted sequencing and immunohistochemistry of known driver genes. Exome sequencing was performed in 10 patients who had either unusually long survival (N = 5) or had a very short time to progression (N = 5). Results: The majority of mixed OCCC (N = 6, 85.7%) and a small proportion of pure OCCC (N = 3, 4.9%) were reclassified as likely HGSOC. However, the PFS and OS of patients with misclassified samples were similar to that of patients with pathologically validated OCCC. Absent HNF1B expression was significantly correlated with longer PFS and OS (P = 0.0194 and 0.0395, respectively). Mutations in ARID1A, PIK3CA, PPP2R1A, and TP53 were frequent, but did not explain length of PFS and OS. An exploratory exome analysis of patients with favorable and unfavorable outcomes did not identify novel outcome-associated driver mutations. Conclusions: Survival benefit following chemotherapy in OCCC was not associated with pathological misclassification of tumor histotype. HNF1B loss may help identify the subset of patients with OCCC with a more favorable outcome.Keywords
All Related Versions
Funding Information
- NHMRC (APP1092856)
- NHMRC (APP1117044)
- U.S. Army Medical Research and Materiel Command (DAMD17-01-1-0729)
- NHMRC (ID400413, ID400281)
This publication has 49 references indexed in Scilit:
- Napsin A as a marker of clear cell ovarian carcinomaBMC Cancer, 2013
- Signatures of mutational processes in human cancerNature, 2013
- Integrated genomic characterization of endometrial carcinomaNature, 2013
- Histotype-specific copy-number alterations in ovarian cancerBMC Medical Genomics, 2012
- Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinomaLaboratory Investigation, 2012
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- ARID1AMutations in Endometriosis-Associated Ovarian CarcinomasNew England Journal of Medicine, 2010
- Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell CarcinomaScience, 2010
- Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovaryThe Journal of Pathology, 2010
- Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker StudiesPLOS Medicine, 2008